DE

Detlef Bruno Schuppan

This inventor holds 0 USPTO granted patents, plus 1 CIPO patent.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Detlef Bruno Schuppan. Retrieved from https://idiyas.com/inventor/detlef-bruno-schuppan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 1.0

ph-index = 1


Loading Chart...

Title: Detlef Bruno Schuppan: Innovator in Peptide-Based Carrier Devices

Introduction

Detlef Bruno Schuppan is a notable inventor based in Germany. He has made significant contributions to the field of biotechnology, particularly in the development of peptide-based carrier devices. His work focuses on innovative solutions for targeting specific cells in the body, which can lead to advancements in medical therapies.

Latest Patents

Detlef Bruno Schuppan holds a patent for "Peptide-Based Carrier Devices For Stellate Cells." This invention relates to a compound that comprises a carrier molecule linked to a cyclic peptide. The cyclic peptide includes a sequence encoding a cell receptor recognizing peptide (RRP). The compound is designed for use in pharmaceutical compositions aimed at treating various diseases, including fibrotic and sclerotic diseases.

Career Highlights

Detlef Bruno Schuppan is associated with Biorion Technologies B.V., where he continues to work on innovative projects. His research has the potential to impact the treatment of chronic inflammatory processes and other significant health issues. Despite having no patents listed under his name, his contributions to the field are noteworthy.

Collaborations

Detlef has collaborated with notable colleagues, including Klaas Poelstra and Eleonora Beljaars. These partnerships have likely enhanced the scope and impact of his research efforts.

Conclusion

Detlef Bruno Schuppan is a dedicated inventor whose work in peptide-based carrier devices holds promise for future medical applications. His innovative approach to targeting specific cells could lead to significant advancements in therapeutic strategies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…